Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Provexis ( (GB:PXS) ).
Provexis reported unaudited interim revenue of £364,000 for the six months to 30 September 2025, sharply lower than the prior year due to a third‑party delay in a new production run of its Fruitflow II SD ingredient, which temporarily constrained sales in August and September. Despite the short-term impact, the company has since sold out its legacy DSM-sourced inventory, booked and/or taken orders worth several hundred thousand pounds for Fruitflow II SD after the period end, and is planning at least three new production runs over the next 12 months, while continuing to deepen its commercial ties with dsm-firmenich and support BYHEALTH’s large-scale, regulatory-driven launch plans in China that could significantly expand Fruitflow’s global footprint and enhance Provexis’s long-term growth prospects.
The most recent analyst rating on (GB:PXS) stock is a Hold with a £0.82 price target. To see the full list of analyst forecasts on Provexis stock, see the GB:PXS Stock Forecast page.
Spark’s Take on GB:PXS Stock
According to Spark, TipRanks’ AI Analyst, GB:PXS is a Neutral.
The score is held back mainly by persistent operating losses and negative cash flow despite improving revenue momentum and a debt-free balance sheet. Technicals are supportive but appear overbought, while recent corporate updates are constructive on growth initiatives; valuation remains constrained by negative earnings.
To see Spark’s full report on GB:PXS stock, click here.
More about Provexis
Provexis plc is a UK-based functional food and nutraceutical company focused on developing, licensing and selling Fruitflow, a patented, scientifically proven heart-health ingredient derived from tomatoes. The company supplies Fruitflow as the Fruitflow II SD ingredient and as the Fruitflow+ Omega-3 consumer product, targeting food, beverage and dietary supplement manufacturers globally, and works through long-term partnerships with groups such as dsm-firmenich and Chinese dietary supplements giant BYHEALTH to expand its international market reach, including potential use in gut microbiome modulation applications.
Average Trading Volume: 1,410,214
Technical Sentiment Signal: Strong Buy
Current Market Cap: £19.12M
See more data about PXS stock on TipRanks’ Stock Analysis page.